Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation

被引:17
作者
Antunes, Marina V. [1 ,2 ]
da Fontoura Timm, Tatiana Aparecida [2 ]
de Oliveira, Vanessa [2 ]
Staudt, Dilana E. [2 ]
Raymundo, Suziane [2 ]
Goessling, Gustavo [3 ]
Biazus, Jorge V. [3 ]
Cavalheiro, Jose A. [3 ]
Rosa, Daniela D. [4 ]
Wallemacq, Pierre [5 ]
Haufroid, Vincent [5 ]
Linden, Rafael [2 ]
Schwartsmann, Gilberto [1 ,3 ]
机构
[1] Univ Fed Rio Grande do Sul, Fac Med, Posgrad Ciencias Med, Porto Alegre, RS, Brazil
[2] Univ Feevale, Inst Ciencias Saude, Novo Hamburgo, Brazil
[3] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil
[4] Hosp Moinhos de Vento, Porto Alegre, RS, Brazil
[5] Catholic Univ Louvain, Inst Rech Expt & Clin, Louvain Ctr Toxicol & Appl Pharmacol, B-1200 Brussels, Belgium
关键词
tamoxifen; CYP3A4; CYP2D6; vitamin D; endoxifen; 4-hydroxytamoxifen; BREAST-CANCER; CLINICAL-APPLICATION; OMEPRAZOLE SULFONE; MAIN METABOLITES; PLASMA-LEVELS; ENDOXIFEN; GENOTYPE; CYP3A4-ASTERISK-22; POLYMORPHISMS; ASSOCIATION;
D O I
10.1097/FTD.0000000000000212
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objective: In view of the large variability on therapeutic response and the multiple factors associated to tamoxifen (TAM) metabolic activation, this study aimed to evaluate the effect of CYP2D6 and CYP3A4 phenotypes, drug interactions, and vitamin D exposure on TAM metabolism in a group of breast cancer patients. Methods: Trough blood samples were collected from 116 patients. TAM and metabolites endoxifen ( EDF), N- desmethyltamoxifen, and 4- hydroxytamoxifen ( HTF) were measured in plasma by liquid chromatography- tandem mass spectrometry. CYP2D6 and CYP3A4 phenotyping were obtained according to [ dextromethorphan]/[ dextrorphan] and [ omeprazole]/[ omeprazole sulfone] metabolic ratios, measured by high- performance liquid chromatography in plasma collected 3 hours after oral administration of 33 mg of dextromethorphan and 20 mg of omeprazole. Vitamin D3 was measured in plasma by high- performance liquid chromatography- ultraviolet. Data on concomitant use of drug considered as CYP2D6 and CYP3A4 inhibitor or inducer and vitamin D supplementation were recorded. Results: About 20% of patients had reduced CYP2D6 metabolic activity and 7% CYP3A4 impaired metabolism. EDF levels diminished proportionally to the reduction of CYP2D6 metabolic activity ( poor metabolizer 2.79 ng center dot mL-1, intermediate metabolizer ( IM) 5.36 ng center dot mL- 1, and extensive metabolizer 10.65 ng center dot mL21, P<0.01). Median plasma levels of TAM ( 161.50 ng center dot mL21) and HTF ( 1.32 ng center dot mL21) in CYP2D6 IM/ CYP3A4 poor metabolizer patients were higher ( P< 0.05) than those from CYP2D6 IM/ CYP3A4 extensive metabolizer patients ( 122.07 ng center dot mL21 and 0.61 ng center dot mL21, respectively). Seasons contributed to the interpatient variability of EDF and HTF levels; summer concentrations were 24% and 42% higher compared with winter. Vitamin D3 was not associated to CYP3A4 metabolic activity, indicating that other mechanisms might be involved in the relation between TAM metabolism and vitamin D exposure. Conclusions: CYP3A4 contributes to the bioactivation of TAM through formation of HTF and becomes increasingly important in case of reduced or absent CYP2D6 activity. EDF and HTF exposure were associated to seasonal variations, with considerable higher plasma concentrations during summer.
引用
收藏
页码:733 / 744
页数:12
相关论文
共 39 条
[1]   Simple chromatography method for simultaneous determination of dextromethorphan and its main metabolites in human plasma with fluorimetric detection [J].
Afshar, M ;
Rouini, MR ;
Amini, M .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 802 (02) :317-322
[2]  
Ahsen NV, 2009, J LAB MED, V33, P1
[3]   Endoxifen Levels and Its Association With CYP2D6 Genotype and Phenotype: Evaluation of a Southern Brazilian Population Under Tamoxifen Pharmacotherapy [J].
Antunes, Marina V. ;
Linden, Rafael ;
Santos, Tamyris V. ;
Wallemacq, Pierre ;
Haufroid, Vincent ;
Classen, Jean-Francois ;
Andreolla, Huander ;
Costa, Nathalia ;
Fontanive, Tiago O. ;
Rosa, Daniela D. .
THERAPEUTIC DRUG MONITORING, 2012, 34 (04) :422-431
[4]  
Antunes MV, 2015, PHARMACOGENOMICS, V16, P601, DOI [10.2217/PGS.15.13, 10.2217/pgs.15.13]
[5]   Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots-Development, validation and clinical application during breast cancer adjuvant therapy [J].
Antunes, Marina Venzon ;
Raymundo, Suziane ;
de Oliveira, Vanessa ;
Staudt, Dilana Elisabeth ;
Goessling, Gustavo ;
Peteffi, Giovana Piva ;
Biazus, Jorge Villanova ;
Cavalheiro, Jose Antonio ;
Tre-Hardy, Marie ;
Capron, Arnaud ;
Haufroid, Vincent ;
Wallemacq, Pierre ;
Schwartsmann, Gilberto ;
Linden, Rafael .
TALANTA, 2015, 132 :775-784
[6]   Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients [J].
Antunes, Marina Venzon ;
Staudt, Dilana Elisabeth ;
Raymundo, Suziane ;
de Oliveira, Vanessa ;
Goessling, Gustavo ;
Pirolli, Rafaela ;
Biazus, Jorge Villanova ;
Cavalheiro, Jose Antonio ;
Rosa, Daniela Dornelles ;
Schwartsmann, Gilberto ;
Linden, Rafael .
CLINICAL BIOCHEMISTRY, 2014, 47 (12) :1084-1090
[7]   Vitamin D supplementation and total mortality - A meta-analysis of randomized controlled trials [J].
Autier, Philippe ;
Gandini, Sara .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (16) :1730-1737
[8]   Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22 [J].
Baxter, Simon D. ;
Teft, Wendy A. ;
Choi, Yun-Hee ;
Winquist, Eric ;
Kim, Richard B. .
BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (02) :419-428
[9]   CYP2D6 Polymorphisms and the impact on tamoxifen therapy [J].
Beverage, Jacob N. ;
Sissung, Tristan M. ;
Sion, Amy M. ;
Danesi, Romano ;
Figg, William D. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (09) :2224-2231
[10]   The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users [J].
Bijl, Monique J. ;
van Schaik, Ron H. N. ;
Lammers, Laureen A. ;
Hofman, Albert ;
Vulto, Arnold G. ;
van Gelder, Teun ;
Stricker, Bruno H. Ch. ;
Visser, Loes E. .
BREAST CANCER RESEARCH AND TREATMENT, 2009, 118 (01) :125-130